Neutralizing antibodies have been shown to protect against HIV challenge in some of the best available animal models. Antibodies given intravenously can protect macaques against intravenous or mucosal SHIV challenge and topically applied antibodies can protect macaques against vaginal SHIV challenge. The mechanisms of this protection are not understood. It is often assumed that neutralization of free virus particles, as measured in classical in vitro assays, is solely responsible because protection is afforded by neutralizing antibodies. However neutralizing antibodies can also mediate a number of other anti-viral activities, notably against infected cells. These include effector functions such as complement activation and antibody dependent cellular cytotoxicity mediated by the Fc part of the antibody molecule. The critical importance of effector functions for antibody-mediated protection against a number of viruses has been well documented in the literature. The purpose of this application is to explore the importance of effector function in antibody-mediated protection against HIV. It is proposed to investigate the ability of a panel of antibody molecules, derived from the human neutralizing antibody IgG1b12, to protect against vaginal challenge with an R5 SHIV in macaques. The conditions for intravenously or topically administered IgG1b12 to protect against vaginal challenge have been established previously. The current application makes use of a panel of IgG1 b12variants in which effector functions have been specifically disabled to better understand the role of effector functions in systemic and mucosal antibody-mediated protection. In addition, a secretory IgA version of b12 (SIgA2b12) will be used to compare the ability of mucosal IgA and IgG to protect and to reveal the importance of functions associated with SIgA in protection. The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI055332-03
Application #
6884619
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
D'Souza, Patricia D
Project Start
2003-05-15
Project End
2008-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
3
Fiscal Year
2005
Total Cost
$787,723
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
von Bredow, Benjamin; Arias, Juan F; Heyer, Lisa N et al. (2016) Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. J Virol 90:6127-6139
Diebolder, Christoph A; Beurskens, Frank J; de Jong, Rob N et al. (2014) Complement is activated by IgG hexamers assembled at the cell surface. Science 343:1260-3
Li, Qingsheng; Zeng, Ming; Duan, Lijie et al. (2014) Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 193:3113-25
Barouch, Dan H; Whitney, James B; Moldt, Brian et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224-8
Jaworski, J Pablo; Kobie, James; Brower, Zachary et al. (2013) Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol 87:10447-59
Moldt, Brian; Shibata-Koyama, Mami; Rakasz, Eva G et al. (2012) A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc?RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 86:6189-96
Ackerman, Margaret E; Moldt, Brian; Wyatt, Richard T et al. (2011) A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366:8-19
Moldt, Brian; Schultz, Niccole; Dunlop, D Cameron et al. (2011) A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc? receptors to define the role of effector functions in protection against HIV. J Virol 85:10572-81
Weinfurter, Jason T; May, Gemma E; Soma, Taeko et al. (2011) Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus. J Virol 85:530-41
Hessell, Ann J; Poignard, Pascal; Hunter, Meredith et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-4

Showing the most recent 10 out of 12 publications